Clinical effectiveness of interventions for treatment-resistant anxiety in older people: a systematic review
Open accessThe DOI matches its Crossref record; 174 of the 175 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Anxiety and related disorders include generalised anxiety disorder, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder and phobic disorders (intense fear of an object or situation). These disorders share the psychological and physical symptoms of anxiety, but each disorder has its own set of characteristic symptoms. Anxiety disorders can be difficult to recognise, particularly in older people (those aged over 65 years). Older people tend to be more reluctant to discuss mental health issues and there is the perception that older people are generally more worried than younger adults. It is estimated that between 3 and 14 out of every 100 older people have an anxiety disorder. Despite treatment, some people will continue to have symptoms of anxiety. People are generally considered to be 'resistant' or 'refractory' to treatment if they have an inadequate response or do not respond to their first treatment. Older adults with an anxiety disorder find it difficult to manage their day-to-day lives and are at an increased risk of comorbid depression, falls, physical and functional disability, and loneliness. OBJECTIVE: To evaluate the effectiveness of pharmacological, psychological and alternative therapies in older adults with an anxiety disorder who have not responded, or have responded inadequately, to treatment. DATA SOURCES: Electronic databases (MEDLINE, MEDLINE In-Process and Other Non-Indexed citations, EMBASE, The Cochrane Library databases, PsycINFO and Web of Science) were searched from inception to September 2013. Bibliographies of relevant systematic reviews were hand-searched to identify additional potentially relevant studies. ClinicalTrials.gov was searched for ongoing and planned studies. REVIEW METHODS: A systematic review of the clinical effectiveness of treatments for treatment-resistant anxiety in older adults was carried out. RESULTS: No randomised controlled trial or prospective comparative observational study was identified meeting the prespecified inclusion criteria. Therefore, it was not possible to draw any conclusions on clinical effectiveness. LIMITATIONS: As no study was identified in older adults, there is uncertainty as to which treatments are clinically effective for older adults with an anxiety disorder who have not responded to prior treatment. The comprehensive methods implemented to carry out this review are a key strength of the research presented. However, this review highlights the extreme lack of research in this area, identifying no comparative studies, which is a marked limitation. CONCLUSIONS: Specific studies evaluating interventions in older adults with an anxiety disorder who have not responded to first-line treatment are needed to address the lack of evidence. The lack of evidence in this area means that older adults are perhaps receiving inappropriate treatment or are not receiving a particular treatment because there is limited evidence to support its use. At this time there is scope to develop guidance on service provision and, as a consequence, to advance the standard of care received by older adults with a treatment-resistant anxiety disorder in primary and secondary care. Evaluation of the relative clinical effectiveness and acceptability of pharmacological and psychological treatment in older adults with an anxiety disorder that has not responded to first-line treatment is key future research to inform decision-making of clinicians and patients. An important consideration would be the enrolment of older adults who would be representative of older adults in general, i.e. those with multiple comorbid physical and mental disorders who might require polypharmacy. STUDY REGISTRATION: The protocol for the systematic review is registered on PROSPERO (registration number CRD42013005612). FUNDING: The National Institute for Health Research Health Technology Assessment programme.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As noted in Chapter 1, guidance on managing TR-GAD in older people (and indeed in working-age people) is lacking.”
From Acceptance and commitment therapy for older people with treatment-resistant generalised anxiety disorder: The FACTOID feasibility study (2021) · cites this paper as [35]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A previous systematic review 35 was unable to identify any randomised controlled trial (RCT) or prospective comparative study of either pharmacological or psychological interventions for treatment-resistant anxiety in older people.”
From Acceptance and commitment therapy for older people with treatment-resistant generalised anxiety disorder: The FACTOID feasibility study (2021) · cites this paper as [35]
The cited source says what the claim attributes to it.
In the citing paper
“A previous systematic review 35 was unable to identify any randomised controlled trial (RCT) or prospective comparative study of either pharmacological or psychological interventions for treatment-resistant anxiety in older people.”
From Acceptance and commitment therapy for older people with treatment-resistant generalised anxiety disorder: The FACTOID feasibility study (2021) · cites this paper as [35]
The cited source says what the claim attributes to it.
In the citing paper
“For example, a previous systematic review was unable to identify any randomised controlled trial (RCT) or prospective comparative observational study of pharmacotherapy or psychotherapy for treatment-resistant anxiety in older people [8].”
From Acceptance and commitment therapy for late-life treatment-resistant generalised anxiety disorder: a feasibility study. (2021) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Merikangas, K. R., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.593 · Cited by 20,391 · cited 1×
“A US-based study (9282 English-speaking respondents aged ≥ 18 years) reported the median age at onset of anxiety disorders to be 11 years.(2) Although anxiety disorders among older people (≥ 65 years) are less common than in younger adults, it is acknowledged that the frequency in older adults is considerably higher t…”
Diagnostic and Statistical Manual of Mental Disorders.
Widiger, T. A. (2000) · Encyclopedia of Psychology, Vol. 3. · doi:10.1037/10518-009 · Cited by 19,744
Hao (2015) · doi:10.1002/14651858 · Cited by 11,321
Neural regulation of endocrine and autonomic stress responses
Ulrich-Lai, Y. M., & Herman, J. P. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2647 · Cited by 3,318 · cited 3×
“When a threat is perceived, various neurotransmitters and other chemical messengers, including circulating hormones, are released to modulate the neural circuitry involved in the generation of feelings of fear and anxiety.(22) The chief hormone involved in the autonomic nervous system is the catecholamine ‘adrenaline’…”
The HPA axis in major depression: classical theories and new developments
Pariante, C. M., & Lightman, S. L. (2008) · Trends in Neurosciences · doi:10.1016/j.tins.2008.06.006 · Cited by 2,009 · cited 1×
“Dysregulation of the hypothalamo–pituitary–adrenal axis is known to be associated with an increased risk of development of major depression.(24) Furthermore, the ageing brain is less able to downregulate the hypothalamo–pituitary–adrenal axis and is more susceptible to physiological stressors.”
Julian, L. J. (2011) · Arthritis Care & Research · doi:10.1002/acr.20561 · Cited by 1,794 · cited 2×
“By contrast, the Hospital Anxiety and Depression Scale evaluates the presence of symptoms of anxiety and depression in physically ill people.(18) The effects of variation in language, education and culture across ethnic groups can lead to variation in judging the severity of patients’ symptoms.”
Smaller hippocampal volume predicts pathologic vulnerability to psychological trauma
Gilbertson, M. W., Shenton, M. E., Ciszewski, A., Kasai, K., Lasko, N. B., Orr, S. P., & Pitman, R. K. (2002) · Nature Neuroscience · doi:10.1038/nn958 · Cited by 1,635 · cited 1×
“However, recent research involving identical (monozygotic) twins suggests that reduced hippocampal volume is predetermined and volume is linked with susceptibility to PTSD.(33) Other studies in identical or non-identical (dizygotic) twins have found that all the anxiety disorders have a moderately strong genetic basis…”
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.7.973 · Cited by 1,610
A Review and Meta-Analysis of the Genetic Epidemiology of Anxiety Disorders
Hettema, J. M., Neale, M. C., & Kendler, K. S. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.10.1568 · Cited by 1,563 · cited 1×
“Other studies in identical or non-identical (dizygotic) twins have found that all the anxiety disorders have a moderately strong genetic basis, accounting for 30–40% of the probability of a person developing an anxiety disorder.(34,35)”
Unraveling the mysteries of anxiety and its disorders from the perspective of emotion theory.
Barlow, D. H. (2000) · American Psychologist · doi:10.1037/0003-066x.55.11.1247 · Cited by 1,135 · cited 1×
“However, one environmental factor known to be linked with the risk of a person developing an anxiety disorder is the childhood relationship with parents.(36,37) Positive parenting experiences are important to provide children with a feeling of security.”
Subthalamic nucleus stimulation in severe obsessive-compulsive disorder
Mallet, L., Polosan, M., Jaafari, N., Baup, N., Welter, M.-L., Fontaine, D., Montcel, S. T. D., Yelnik, J., Chéreau, I., Arbus, C., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708514 · Cited by 965
Hippocampal volume in women victimized by childhood sexual abuse
STEIN, M. B., KOVEROLA, C., HANNA, C., TORCHIA, M. G., & McCLARTY, B. (1997) · Psychological Medicine · doi:10.1017/s0033291797005242 · Cited by 924
Gurvits, T. V., Shenton, M. E., Hokama, H., Ohta, H., Lasko, N. B., Gilbertson, M. W., Orr, S. P., Kikinis, R., Jolesz, F. A., McCarley, R. W., et al. (1996) · Biological Psychiatry · doi:10.1016/s0006-3223(96)00229-6 · Cited by 900
Kim, M. J., Loucks, R. A., Palmer, A. L., Brown, A. C., Solomon, K. M., Marchante, A. N., & Whalen, P. J. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.04.025 · Cited by 838 · cited 2×
“The amygdala is located deep in the anterior medial section of each temporal lobe and is thought to be involved in memory storage and communication.(27) It is thought that the amygdala facilitates signal transfer between the components of the brain that process incoming sensory signals and those that interpret the sig…”
Antidepressant use and risk of adverse outcomes in older people: population based cohort study
Coupland, C., Dhiman, P., Morriss, R., Arthur, A., Barton, G., & Hippisley-Cox, J. (2011) · BMJ · doi:10.1136/bmj.d4551 · Cited by 833 · cited 1×
“A systematic review on the risk of adverse effects associated with antidepressant use in older adults identified a statistically significant increase in the risk of falls and of fractures with use of TCAs.(75) Initially a low dose should be used and patients should be monitored closely, particularly checking for psych…”
Sareen, J., Cox, B. J., Afifi, T. O., de Graaf, R., Asmundson, G. J. G., ten Have, M., & Stein, M. B. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.11.1249 · Cited by 824 · cited 1×
“The presence of an anxiety disorder has been identified as an independent risk factor for subsequent onset of suicidal ideation and attempts.(42) In all age groups, the frequent comorbidity of anxiety disorders, depression, and alcohol and drug misuse complicates the evaluation of long-term prognosis.”
Adult psychiatric morbidity in England, 2007: Results of a household survey
Mcmanus, S., Meltzer, H., Brugha, T., Bebbington, P., & Jenkins, R. (2009) · Unpublished · doi:10.13140/2.1.1563.5205 · Cited by 814
Hippocampal damage associated with prolonged and fatal stress in primates
Uno, H., Tarara, R., Else, J., Suleman, M., & Sapolsky, R. (1989) · The Journal of Neuroscience · doi:10.1523/jneurosci.09-05-01705.1989 · Cited by 728 · cited 1×
“The culmination of the various signalling interactions is the release of adrenal hormones, called glucocorticoids, of which cortisol is the most important.(22,23) Cortisol causes a rapid release of the body’s energy stores to maintain blood sugar levels and also suppresses any immune response.”
Anxiety disorders in older adults: a comprehensive review
Wolitzky-Taylor, K. B., Castriotta, N., Lenze, E. J., Stanley, M. A., & Craske, M. G. (2010) · Depression and Anxiety · doi:10.1002/da.20653 · Cited by 726 · cited 10×
“Disorders affecting physical health are common in older adults, and older adults are more likely to attribute their symptoms of anxiety to their physical illness, which could result in non-diagnosis of their anxiety disorder.(1) Development of an anxiety disorder has been linked with thyroid problems (e.”
InfluentialMithoefer, M. C., Wagner, M. T., Mithoefer, A. T., Jerome, L., & Doblin, R. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110378371 · Cited by 674
SSRI Antidepressant Medications: Adverse Effects and Tolerability
Ferguson, J. M. (2001) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v03n0105 · Cited by 669 · cited 1×
“Selective serotonin reuptake inhibitors are the first choice of pharmacological treatment for anxiety disorders and major depression because they have a better tolerability and adverse effect profile than other classes of antidepressants.(72) In particular, compared with TCAs, the SSRIs do not cause cardiac conduction…”
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Bandelow, B., Bond, A., Davidson, J. R. T., den Boer, J. A., Fineberg, N. A., Knapp, M., Scott, J., et al. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105059253 · Cited by 617 · cited 1×
“buspirone).(70) In addition, augmentation of ongoing pharmacotherapy with an antipsychotic agent has been found to be clinically effective at improving symptoms of anxiety in treatment-resistant anxiety disorders.”
Self-citationRaskind, M. A., Peskind, E. R., Kanter, E. D., Petrie, E. C., Radant, A., Thompson, C. E., Dobie, D. J., Hoff, D., Rein, R. J., Straits-Tröster, K., et al. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.2.371 · Cited by 607
McDougle, C. J., Epperson, C. N., Pelton, G. H., Wasylink, S., & Price, L. H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.8.794 · Cited by 571
McDougle, C. J. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950040046006 · Cited by 570
The developmental origins of anxiety
Gross, C., & Hen, R. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1429 · Cited by 566 · cited 5×
“The discovery that anxiolytic (anti-anxiety) drugs interact with neurotransmitters led to the proposal that abnormal activity in the brain is a physiological characteristic of anxiety.(21)”
InfluentialDeep brain stimulation for refractory obsessive-compulsive disorder
Abelson, J. L., Curtis, G. C., Sagher, O., Albucher, R. C., Harrigan, M., Taylor, S. F., Martis, B., & Giordani, B. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.11.042 · Cited by 522
Clomipramine Treatment of Obsessive-Compulsive Disorder: I. A Controlled Clinical Trial
Thorén, P. (1980) · Archives of General Psychiatry · doi:10.1001/archpsyc.1980.01780240079009 · Cited by 497
Long-term Electrical Capsular Stimulation in Patients with Obsessive-Compulsive Disorder
Nuttin, B. J., Gabriëls, L. A., Cosyns, P. R., Meyerson, B. A., Andréewitch, S., Sunaert, S. G., Maes, A. F., Dupont, P. J., Gybels, J. M., Gielen, F., et al. (2003) · Neurosurgery · doi:10.1227/01.neu.0000064565.49299.9a · Cited by 487
Principles of pharmacology : the pathophysiologic basis of drug therapy
Golan, D. E., & Tashjian, A. H. (2012) · Cited by 469
Tarrier, N., Pilgrim, H., Sommerfield, C., Faragher, B., Reynolds, M., Graham, E., & Barrowclough, C. (1999) · Journal of Consulting and Clinical Psychology · doi:10.1037//0022-006x.67.1.13 · Cited by 462
Efficacy and Safety of Paroxetine Treatment for Chronic PTSD: A Fixed-Dose, Placebo-Controlled Study
Marshall, R. D., Beebe, K. L., Oldham, M., & Zaninelli, R. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.12.1982 · Cited by 432
Prevalence of anxiety disorders and their comorbidity with mood and addictive disorders
Regier, D. A., Rae, D. S., Narrow, W. E., Kaelber, C. T., & Schatzberg, A. F. (1998) · British Journal of Psychiatry · doi:10.1192/s0007125000293483 · Cited by 407
Tyrer, P., & Baldwin, D. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69865-6 · Cited by 404
Self-citationGoodman, W. K., Foote, K. D., Greenberg, B. D., Ricciuti, N., Bauer, R., Ward, H., Shapira, N. A., Wu, S. S., Hill, C. L., Rasmussen, S. A., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.11.028 · Cited by 362
Sareen, J., Jacobi, F., Cox, B. J., Belik, S.-L., Clara, I., & Stein, M. B. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.19.2109 · Cited by 361 · cited 1×
“hypothyroidism or hyperthyroidism), respiratory and gastrointestinal conditions, arthritis, migraine headaches and allergic conditions.(7)”
Stein, M. B., Kline, N. A., & Matloff, J. L. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.10.1777 · Cited by 347
Hinton, D. E., Chhean, D., Pich, V., Safren, S. A., Hofmann, S. G., & Pollack, M. H. (2005) · Journal of Traumatic Stress · doi:10.1002/jts.20070 · Cited by 332
Eaton, W. W., Kramer, M., Anthony, J. C., Dryman, A., Shapiro, S., & Locke, B. Z. (1989) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1989.tb08584.x · Cited by 326 · cited 1×
“Most people with a primary anxiety disorder experienced the onset of the condition before the age of 41 years (90%), with 75% of people diagnosed with an anxiety disorder before the age of 21 years.(46)”
Huff, W., Lenartz, D., Schormann, M., Lee, S.-H., Kuhn, J., Koulousakis, A., Mai, J., Daumann, J., Maarouf, M., Klosterkötter, J., et al. (2010) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2009.11.006 · Cited by 315
Neuroimaging in social anxiety disorder: a systematic review of the literature
Freitas-Ferrari, M. C., Hallak, J. E. C., Trzesniak, C., Filho, A. S., Machado-de-Sousa, J. P., Chagas, M. H. N., Nardi, A. E., & Crippa, J. A. S. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.02.028 · Cited by 298 · cited 2×
“Imaging of brain activity during exposure to triggers of anxiety has suggested that the amygdala and the hippocampus have an integral role in eliciting feelings of fear and anxiety.(21,26) The amygdala is located deep in the anterior medial section of each temporal lobe and is thought to be involved in memory storage…”
Treatment-resistant anxiety disorders
Bystritsky, A. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001852 · Cited by 289 · cited 2×
“It has been recommended that the assessment of remission and recovery in anxiety disorders includes an assessment of functional status.(38) Recognition of treatment resistance is further complicated by the frequent presence of symptoms of more than one anxiety disorder and the presence of a comorbid disorder that pote…”
Mantovani, A., Simpson, H. B., Fallon, B. A., Rossi, S., & Lisanby, S. H. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709990435 · Cited by 281
Gould, R. L., Coulson, M. C., & Howard, R. J. (2012) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2011.03824.x · Cited by 267
Buspirone: review of its pharmacology and current perspectives on its mechanism of action
Eison, A. S., & Temple, D. L. (1986) · The American Journal of Medicine · doi:10.1016/0002-9343(86)90325-6 · Cited by 258 · cited 1×
“it binds to, and activates, a specific serotonin receptor, but has only partial efficacy compared with a full agonist).(80) Primarily used to treat GAD, the pharmacological profile of buspirone is different from other anxiolytics in that it alleviates symptoms of anxiety without the associated effects of sedation or f…”
CBT for Vietnamese refugees with treatment‐resistant PTSD and panic attacks: A pilot study
Hinton, D. E., Pham, T., Tran, M., Safren, S. A., Otto, M. W., & Pollack, M. H. (2004) · Journal of Traumatic Stress · doi:10.1023/b:jots.0000048956.03529.fa · Cited by 252
Cognitive-behavioral treatment of late-life generalized anxiety disorder
Stanley, M. A., Beck, J. G., Novy, D. M., Averill, P. M., Swann, A. C., Diefenbach, G. J., & Hopko, D. R. (2003) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.71.2.309 · Cited by 247
Ninan, P. T., Koran, L. M., Kiev, A., Davidson, J. R. T., Rasmussen, S. A., Zajecka, J. M., Robinson, D. G., Crits-Christoph, P., Mandel, F. S., & Austin, C. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0103 · Cited by 245
Phenomenology and Course of Generalised Anxiety Disorder
Yonkers, K. A., Warshaw, M. G., Massion, A. O., & Keller, M. B. (1996) · British Journal of Psychiatry · doi:10.1192/bjp.168.3.308 · Cited by 242 · cited 2×
“One US-based study evaluating people with GAD (164 people) reported a mean age at onset of an anxiety disorder of 21 years and an average duration of illness of about 20 years.(40) Studies suggest that anxiety disorders are more chronic than other common mental disorders and that comorbid depression and anxiety has a…”
A lifespan view of anxiety disorders
Lenze, E. J., & Wetherell, J. L. (2011) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2011.13.4/elenze · Cited by 227 · cited 1×
“Furthermore, the ageing brain is less able to downregulate the hypothalamo–pituitary–adrenal axis and is more susceptible to physiological stressors.(25) Thus, in older adults chronic anxiety can cause hyperactivity of this system, which can detrimentally affect memory and executive function.”
Krystal, J. H., Rosenheck, R. A., Cramer, J. A., Vessicchio, J. C., Jones, K. M., Vertrees, J. E., Horney, R. A., Huang, G. D., Stock, C., & for the Veterans Affairs Cooperative Study No. 504 Group (2011) · JAMA · doi:10.1001/jama.2011.1080 · Cited by 220
Okun, M. S., Mann, G., Foote, K. D., Shapira, N. A., Bowers, D., Springer, U., Knight, W., Martin, P., & Goodman, W. K. (2006) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2006.095315 · Cited by 214
Hollander, E., Rossi, N. B., Sood, E., & Pallanti, S. (2003) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145703003730 · Cited by 197
Neuroimaging studies in post-traumatic stress disorder
Bremner, J. D. (2002) · Current Psychiatry Reports · doi:10.1007/s11920-996-0044-9 · Cited by 194
Lippitz, B. E., Mindus, P., Meyerson, B. A., Kihlström, L., & Lindquist, C. (1999) · Neurosurgery · doi:10.1097/00006123-199903000-00005 · Cited by 189
Lewis, C., Pearce, J., & Bisson, J. I. (2012) · British Journal of Psychiatry · doi:10.1192/bjp.bp.110.084756 · Cited by 189 · cited 2×
“It should be noted that the evidence in this review is based on a synthesis of data from trials in various anxiety disorders and moderate statistical heterogeneity (44%) was present.(57) Considered separately, the evidence base for the effectiveness of self-help in the individual anxiety disorders is limited.”
Carr, C., d’Ardenne, P., Sloboda, A., Scott, C., Wang, D., & Priebe, S. (2012) · Psychology and Psychotherapy: Theory, Research and Practice · doi:10.1111/j.2044-8341.2011.02026.x · Cited by 183
Adjunctive risperidone in the treatment of chronic combat-related posttraumatic stress disorder
Bartzokis, G., Lu, P. H., Turner, J., Mintz, J., & Saunders, C. S. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.11.039 · Cited by 182
Repetitive TMS combined with exposure therapy for PTSD: A preliminary study
Osuch, E. A., Benson, B. E., Luckenbaugh, D. A., Geraci, M., Post, R. M., & McCann, U. (2009) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2008.03.015 · Cited by 180
Hartling, L., Abou-Setta, A. M., Dursun, S. M., Mousavi, S. S., Pasichnyk, D., & Newton, A. S. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-7-201210020-00525 · Cited by 177 · cited 5×
“Common adverse effects associated with first-generation antipsychotics include extrapyramidal symptoms (which involve motor control).(76) Compared with second-generation antipsychotics, first-generation antipsychotics increase the risk of hyperprolactinaemia.”
InfluentialThe role of serotonin in depression and anxiety
Baldwin, D., & Rudge, S. (1995) · International Clinical Psychopharmacology · doi:10.1097/00004850-199501004-00006 · Cited by 174 · cited 1×
“involving serotonin and noradrenaline has long been thought to have a role in the pathogenesis of anxiety and depression.(71) It is thought that SSRIs and SNRIs alleviate symptoms of anxiety and depression by blocking reuptake and, thus, increasing the levels of serotonin and noradrenaline available.”
Self-citationHinton, D. E., Hofmann, S. G., Pollack, M. H., & Otto, M. W. (2009) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2009.00100.x · Cited by 173
Sachdev, P. S., Loo, C. K. A., Mitchell, P. B., McFarquhar, T. F., & Malhi, G. S. (2007) · Psychological Medicine · doi:10.1017/s0033291707001092 · Cited by 169
Hinton, D. E., Hofmann, S. G., Rivera, E., Otto, M. W., & Pollack, M. H. (2011) · Behaviour Research and Therapy · doi:10.1016/j.brat.2011.01.005 · Cited by 168
Improving access to psychological therapies
Wild, S. (2007) · Independent Nurse · doi:10.12968/indn.2007.1.5.74836 · Cited by 166
McDougle, C. J., Price, L. H., Goodman, W. K., Charney, D. S., & Heninger, G. R. (1991) · PubMed · Cited by 161
Katz, I. R., Reynolds, C. F., Alexopoulos, G. S., & Hackett, D. (2002) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2002.50003.x · Cited by 158
Cairney, J., Corna, L., Veldhuizen, S., Herrmann, N., & Streiner, D. L. (2008) · American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000300627.93523.c8 · Cited by 154
Shapira, N. A., Ward, H. E., MANDOKI, M. W., Murphy, T. K., Yang, M. C. K., Blier, P., & Goodman, W. K. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2003.11.010 · Cited by 154
Memantine Augmentation in Treatment-Resistant Obsessive-Compulsive Disorder: An Open-Label Trial
Aboujaoude, E. N., Barry, J. J., & Gamel, N. N. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318192e9a4 · Cited by 147
Pollack, M. H., Simon, N. M., Zalta, A. K., Worthington, J. J., Hoge, E. A., Mick, E. O., Kinrys, G., & Oppenheimer, J. E. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.07.005 · Cited by 146
Atmaca, M., Kuloğlu, M. M., Tezcan, E., & Geçici, Ö. (2002) · International Clinical Psychopharmacology · doi:10.1097/00004850-200205000-00004 · Cited by 146
A Double-Blind Switch Study of Paroxetine and Venlafaxine in Obsessive-Compulsive Disorder
Denys, D. A. J. P., van Megen, H. J. G. M., van der Wee, N. J. A., & Westenberg, H. G. M. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0106 · Cited by 144
The genetics of obsessive compulsive disorder: a review of the evidence
Pauls, D. L. (2008) · American Journal of Medical Genetics Part C: Seminars in Medical Genetics · doi:10.1002/ajmg.c.30168 · Cited by 142 · cited 1×
“Other studies in identical or non-identical (dizygotic) twins have found that all the anxiety disorders have a moderately strong genetic basis, accounting for 30–40% of the probability of a person developing an anxiety disorder.(34,35)”
Right Versus Left Prefrontal Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder
Sachdev, P. S., McBride, R., Loo, C. K. A., Mitchell, P. B., Malhi, G. S., & Croker, V. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n1211 · Cited by 139
Erzegovesi, S., Guglielmo, E., Siliprandi, F., & Bellodi, L. (2004) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2004.04.004 · Cited by 138
Anxiety and anxiety disorders in the old and very old—Results from the Berlin aging study (BASE)
Schaub, R., & LINDEN, M. E. L. V. D. (2000) · Comprehensive Psychiatry · doi:10.1016/s0010-440x(00)80008-5 · Cited by 136 · cited 1×
“4% of those with an anxiety disorder had a comorbid depressive disorder.(6) In comparison, 20% of younger adults (aged 18–54 years) with a diagnosis of any anxiety disorder in the previous 6 months are likely to receive a simultaneous diagnosis of some type of mood disorder.”
Skapinakis, P., Papatheodorou, T., & Mavreas, V. G. (2006) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2006.07.002 · Cited by 136
Praško, J. P., Paskova, B., Záleský, R., Novák, T., Kopeček, M., Bareš, M., & Horáček, J. (2006) · PubMed · Cited by 134
Meta-analysis comparing different behavioral treatments for late-life anxiety
Thorp, S. R., Ayers, C. R., Nuevo, R., Stoddard, J. A., Sorrell, J. T., & Wetherell, J. L. (2009) · The American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e31818b3f7e · Cited by 134 · cited 1×
“Benzodiazepines are also associated with a considerable increase in the risk of falls for an older person.(61)”
A Controlled Trial of Lithium Augmentation in Fluvoxamine-Refractory Obsessive-Compulsive Disorder
McDougle, C. J., Price, L. H., Goodman, W. K., Charney, D. S., & Heninger, G. R. (1991) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199106000-00005 · Cited by 134
Carey, P. D., Vythilingum, B., Seedat, S., Muller, J. E., van Ameringen, M., & Stein, D. J. (2005) · BMC Psychiatry · doi:10.1186/1471-244x-5-5 · Cited by 133
Double-Blind Treatment With Oral Morphine in Treatment-Resistant Obsessive-Compulsive Disorder
Koran, L. M., Aboujaoude, E. N., Bullock, K. D., Franz, B., Gamel, N. N., & Elliott, M. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0312 · Cited by 132
McDougle, C. J., Goodman, W. K., Leckman, J. F., Holzer, J. C., Barr, L. C., McCance‐Katz, E. F., Heninger, G. R., & Price, L. H. (1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.4.647 · Cited by 127
Pinquart, M., & Duberstein, P. R. (2007) · The American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e31806841c8 · Cited by 126 · cited 1×
“pharmacological and psychological treatments for anxiety in older adults highlights the increasing awareness of the need to manage this condition.(3,93,94)”
Simon, N. M., Connor, K. M., Lang, A. J., Rauch, S. A. M., Krulewicz, S., LeBeau, R. T., Davidson, J. R. T., Stein, M. B., Otto, M. W., Foa, E. B., et al. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0309 · Cited by 126
Hofmann, S. G., Sawyer, A. T., Korte, K. J., & Smits, J. A. J. (2009) · International Journal of Cognitive Therapy · doi:10.1521/ijct.2009.2.2.160 · Cited by 126
Parental representations of patients with panic disorder and generalised anxiety disorder
Silove, D., Parker, G., Hadzi-Pavlovic, D., Manicavasagar, V., & Blaszczynski, A. (1991) · British Journal of Psychiatry · doi:10.1192/bjp.159.6.835 · Cited by 122 · cited 2×
“Family conflict, lack of structure and discipline, and overprotection, amongst others, have been identified as parental experiences that predispose a person to developing an anxiety disorder, either during childhood or in later life.(37)”
Adjunctive Risperidone in Generalized Anxiety Disorder
Brawman‐Mintzer, O., Knapp, R. G., & Nietert, P. J. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n1016 · Cited by 122
Muscatello, M. R. A., Bruno, A., Pandolfo, G., Micò, U., Scimeca, G., Romeo, V. M., Santoro, V., Settineri, S., Spina, E., & Zoccali, R. A. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31820e3db6 · Cited by 122
Alterations in brain structure and function associated with post-traumatic stress disorder.
Bremner, J. D. (1999) · PubMed · Cited by 121
Haghighi, M., Jahangard, L., Mohammad-Beigi, H., Bajoghli, H., Hafezian, H., Rahimi, A., Afshar, H., Holsboer‐Trachsler, E., & Brand, S. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3067-z · Cited by 121
TYRER, P., SEIVEWRIGHT, H., & JOHNSON, T. (2004) · Psychological Medicine · doi:10.1017/s0033291704002569 · Cited by 119 · cited 1×
“Studies suggest that anxiety disorders are more chronic than other common mental disorders and that comorbid depression and anxiety has a worse prognosis.(41) The presence of an anxiety disorder has been identified as an independent risk factor for subsequent onset of suicidal ideation and attempts.”
Dannon, P. N., Sasson, Y., Hirschmann, S., Iancu, I., Grunhaus, L. J., & Zohar, J. (2000) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(00)00065-1 · Cited by 116
Kang, J. I., Kim, C., Namkoong, K., Lee, C.-I., & Kim, S. J. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04500 · Cited by 116
Mansur, C. G., Myczkowski, M. L., Cabral, S. D. B., Sartorelli, M. C., Bellini, B. B., Dias, Á. M., Bernik, M., & Marcolin, M. A. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000575 · Cited by 116
Li, X., May, R. S., Tolbert, L. C., Jackson, W. T., Flournoy, J. M., & Baxter, L. R. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0610 · Cited by 110
Matsunaga, H., Nagata, T., Hayashida, K., Ohya, K., Kiriike, N., & Stein, D. J. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04369 · Cited by 110
Intravenous Clomipramine for Obsessive-Compulsive Disorder Refractory to Oral Clomipramine
Fallon, B. A., Liebowitz, M. R., Campeas, R. B., Schneier, F. R., Marshall, R. D., Davies, S. O., Goetz, D., & Klein, D. F. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.10.918 · Cited by 110
Pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders
Ipser, J., Carey, P. D., Dhansay, Y., Fakier, N., Seedat, S., & Stein, D. J. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005473.pub2 · Cited by 110 · cited 3×
“When used as an adjunctive treatment for treatment-resistant anxiety or depression, antipsychotics have predominantly been added to a SSRI (typically fluoxetine).(63,78) A systematic review of augmentation of pharmacotherapy in treatment-resistant anxiety disorders found that augmentation of ongoing therapy with an an…”
Second-generation antipsychotics for anxiety disorders
Depping, A. M., Komossa, K., Kissling, W., & Leucht, S. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008120.pub2 · Cited by 106
Comorbidity of the anxiety disorders in a community‐based older population inThe Netherlands
van Balkom, A. J. L. M., Beekman, A. T. F., de Beurs, E., Deeg, D. J. H., van Dyck, R., & van Tilburg, W. (2000) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2000.101001037.x · Cited by 106
Sayyah, M., Sayyah, M., Boostani, H., Ghaffari, S. M., & Hoseini, A. (2012) · Depression and Anxiety · doi:10.1002/da.21996 · Cited by 105
Optimal treatment of social phobia: systematic review and meta-analysis
Glue, P. (2012) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s23317 · Cited by 105 · cited 1×
“Exposure and response prevention techniques are used in OCD,(68) panic disorder(65) and social anxiety disorder.(67)”
Fineberg, N. A., Sivakumaran, T., Roberts, A., & Gale, T. (2005) · International Clinical Psychopharmacology · doi:10.1097/00004850-200507000-00005 · Cited by 105
Trends in potentially inappropriate prescribing amongst older UK primary care patients
Wilde, S. D., Carey, I. M., Harris, T. J., Richards, N., Victor, C. R., Hilton, S. R., & Cook, D. G. (2006) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1306 · Cited by 104 · cited 2×
“Older adults with an anxiety disorder are most likely to consult their general practitioner and, in this setting, might be inappropriately prescribed a benzodiazepine as an initial treatment.(73) Analysis of patient records from 131 UK general practices (including approximately 162,000 registered patients annually age…”
Fineberg, N. A., Stein, D. J., Premkumar, P., Carey, P., Sivakumaran, T., Vythilingum, B., Seedat, S., Westenberg, H., & Denys, D. (2006) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000215083.57801.11 · Cited by 103
Bruno, A., Micò, U., Pandolfo, G., Mallamace, D., Abenavoli, E., Di Nardo, F., D’Arrigo, C., Spina, E., Zoccali, R. A., & Muscatello, M. R. A. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881111431751 · Cited by 103
Maina, G., Pessina, E., Albert, U., & Bogetto, F. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.01.001 · Cited by 101
Stein, M. B., Sareen, J., Cissell, S. H., & Chao, J. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.10.1725 · Cited by 96
Evidence-based treatment of geriatric anxiety disorders
Wetherell, J. L., Lenze, E. J., & Stanley, M. A. (2005) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2005.09.006 · Cited by 94 · cited 9×
“Considering treatment of anxiety disorders in older adults, systematic reviews of interventions for the treatment of anxiety in later life have found that psychological(93,97) and pharmacological(94) treatments are effective in reducing symptoms of anxiety in this population, with the authors of one review commenting…”
InfluentialKordon, A., Wahl, K., Koch, N., Zurowski, B., Anlauf, M., Vielhaber, K., Kahl, K. G., Broocks, A., Voderholzer, U., & Hohagen, F. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318185e735 · Cited by 92
Ravizza, L., Barzega, G., Bellino, S., Bogetto, F., & Maina, G. (1996) · PubMed · Cited by 90
Psychological treatment of late-life anxiety: An empirical review.
Nordhus, I. H., & Pallesen, S. (2003) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.71.4.643 · Cited by 90 · cited 1×
“pharmacological and psychological treatments for anxiety in older adults highlights the increasing awareness of the need to manage this condition.(3,93,94)”
Hirschmann, S., Dannon, P. N., Iancu, I., Dolberg, O. T., Zohar, J., & Grunhaus, L. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200010000-00011 · Cited by 89
Kampman, M., Keijsers, G. P. J., Hoogduin, C. A. L., & Hendriks, G.-J. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0904 · Cited by 87
Rodgers, M., Asaria, M., Walker, S., McMillan, D., Lucock, M. P., Harden, M., Palmer, S., & Eastwood, A. J. (2012) · Health Technology Assessment · doi:10.3310/hta16280 · Cited by 85 · cited 1×
“Definition of what constitutes low-intensity psychological therapies varies across studies, but such interventions are generally those with little or no involvement of a therapist.(58) Examples include bibliotherapy and computer-guided interventions.”
Diniz, J. B., Shavitt, R. G., Fossaluza, V., Koran, L. M., Pereira, C. A. D. B., & Miguel, E. C. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3182367aee · Cited by 84
Riluzole Augmentation in Treatment-Refractory Obsessive-Compulsive Disorder
Pittenger, C., Kelmendi, B., Wasylink, S., Bloch, M. H., & Coric, V. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181727548 · Cited by 83
Koran, L. M., Aboujaoude, E., & Gamel, N. N. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04605 · Cited by 79
Novel treatment approaches for refractory anxiety disorders
Pollack, M. H., Otto, M. W., Roy-Byrne, P. P., Coplan, J. D., Rothbaum, B. O., Simon, N. M., & Gorman, J. M. (2008) · Depression and Anxiety · doi:10.1002/da.20329 · Cited by 77 · cited 1×
“In clinical trials involving a mixed-age population and different anxiety disorders, remission rates of 20–47% have been reported.(43) The study evaluating people with GAD found that, despite treatment, only 25% of patients achieved symptomatic remission from GAD at 3 years,(40) with a risk of relapse over the subsequ…”
Simon, N. M., Connor, K. M., LeBeau, R. T., Hoge, E. A., Worthington, J. J., Zhang, W., Davidson, J. R. T., & Pollack, M. H. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1087-x · Cited by 72
Edwards, S., Hamilton, V, Nherera, L., & Trevor, N. (2013) · Health Technology Assessment · doi:10.3310/hta17540 · Cited by 71 · cited 1×
“When used as an adjunctive treatment for treatment-resistant anxiety or depression, antipsychotics have predominantly been added to a SSRI (typically fluoxetine).(63,78) A systematic review of augmentation of pharmacotherapy in treatment-resistant anxiety disorders found that augmentation of ongoing therapy with an an…”
Self-citationRickels, K., Shiovitz, T. M., Ramey, T. S., Weaver, J. J., Knapp, L. E., & Miceli, J. J. (2012) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e328350b133 · Cited by 71
Selvı, Y., Atlı, A., Aydın, A., Beşiroğlu, L., Özdemir, P. G., & Özdemir, O. (2011) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1169 · Cited by 70
Macklin, M. L., Metzger, L. J., Lasko, N. B., Berry, N. J., Orr, S. P., & Pitman, R. K. (2000) · Comprehensive Psychiatry · doi:10.1016/s0010-440x(00)90127-5 · Cited by 69
Age differences in treatment response to a collaborative care intervention for anxiety disorders
Wetherell, J. L., Petkus, A. J., Thorp, S. R., Stein, M. B., Chavira, D. A., Campbell-Sills, L., Craske, M. G., Sherbourne, C., Bystritsky, A., Sullivan, G., et al. (2013) · British Journal of Psychiatry · doi:10.1192/bjp.bp.112.118547 · Cited by 65
Hoertel, N., Le Strat, Y., Blanco, C., Lavaud, P., & Dubertret, C. (2012) · Depression and Anxiety · doi:10.1002/da.21937 · Cited by 61 · cited 1×
“People enrolled in clinical trials are relatively homogeneous, having a specific disorder and few or no comorbidities, which does not perhaps represent older adults in general who typically have several comorbid physical or mental health illnesses.(86) Also, most trials have been carried out in an academic setting, wi…”
Naltrexone augmentation in OCD: A double-blind placebo-controlled cross-over study
Amiaz, R., Fostick, L., Gershon, A. A., & Zohar, J. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.01.006 · Cited by 61
Blay, S. L., & Marinho, V. (2012) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e3283578cdd · Cited by 61
Role of pregabalin in the treatment of generalized anxiety disorder
Baldwin, D. S., & Ajel, K. I. (2007) · Neuropsychiatric Disease and Treatment · doi:10.2147/nedt.2007.3.2.185 · Cited by 60 · cited 3×
“As with benzodiazepines, there are concerns about the tolerance of pregabalin during long-term treatment of anxiety disorders and the risk of symptoms of withdrawal on cessation of treatment.(79) Findings from preclinical studies and studies in healthy volunteers are disparate, and uncertainty remains whether or not t…”
InfluentialSelf-citationCsigó, K., Harsányi, A., Demeter, G., Rajkai, C., Németh, A., & Racsmány, M. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.02.127 · Cited by 60
Overcoming resistance to exposure in panic disorder with agoraphobia
Fava, G. A., Savron, G., Zielezny, M., Grandi, S., Rafanelli, C., & Conti, S. (1997) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1997.tb09636.x · Cited by 59
Diniz, J., Shavitt, R. G., Pereira, C. A. D. B., Hounie, A. G., Pimentel, I., Koran, L. M., Dainesi, S., & Miguel, E. C. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881108099423 · Cited by 58
Campanini, R. F. B., Schoedl, A. F., Pupo, M. C., Costa, A. C., KRUPNICK, J. L., & Mello, M. F. (2009) · Depression and Anxiety · doi:10.1002/da.20610 · Cited by 56
Antibiotic and antifungal resistance in antibiotic "free" environment?
Prasko, J., Záleský, R., Bareš, M., Horáček, J., Kopeček, M., Novák, T., & Paskova, B. (2007) · PubMed · Cited by 54
Menza, M. A., Dobkin, R. D., & Marín, H. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000248620.34541.bc · Cited by 51
Adjunctive risperidone treatment and sleep symptoms in combat veterans with chronic PTSD
David, D., Faria, L. D., & Mellman, T. A. (2006) · Depression and Anxiety · doi:10.1002/da.20187 · Cited by 51
Barr, L. C., Goodman, W. K., Anand, A., McDougle, C. J., & Price, L. H. (1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.9.1293 · Cited by 49
Pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders
Dhansay, Y., Ipser, J., & Stein, D. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005473 · Cited by 48
Edwards, S. J., & Smith, C. J. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.07.004 · Cited by 46 · cited 1×
“Second-generation antipsychotics also interact with receptors for neurotransmitters other than dopamine, including serotonin and histamine, and the variation in targeted receptors results in markedly different clinical and adverse effect profiles within the group.(76,77) Choice of treatment is typically determined by…”
Self-citationStorch, E. A., Goddard, A. W., Grant, J. E., Nadai, A. S. D., Goodman, W. K., Mutch, P. J., Medlock, C. E., Odlaug, B. L., McDougle, C. J., & Murphy, T. K. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12m08278 · Cited by 45
Simon, N. M., Otto, M. W., Worthington, J. J., Hoge, E. A., Thompson, E. H., LeBeau, R. T., Moshier, S. J., Zalta, A. K., & Pollack, M. H. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04485blu · Cited by 45
Pulse-Loaded Intravenous Clomipramine in Treatment-Resistant Obsessive-Compulsive Disorder
Koran, L. M., Aboujaoude, E. N., Ward, H. E., Shapira, N. A., Sallee, F. R., Gamel, N. N., & Elliott, M. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000195112.24769.b3 · Cited by 44
Buchsbaum, M. S., Hollander, E., Pallanti, S., Rossi, N. B., Platholi, J., Newmark, R. E., Bloom, R. F., & Sood, E. (2006) · Neuropsychobiology · doi:10.1159/000093342 · Cited by 40
Ziprasidone Treatment of Refractory Generalized Anxiety Disorder
Lohoff, F. W., Etemad, B., Mandos, L. A., Gallop, R., & Rickels, K. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181d21951 · Cited by 38
Augmentative quetiapine in partial/nonresponders with generalized anxiety disorder
Altamura, A. C., Serati, M., Buoli, M., & Dell’Osso, B. M. (2011) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3283457d73 · Cited by 36
Controlled Comparison of Day-patient and Out-patient Treatment for Persistent Anxiety and Depression
DICK, P. H., Sweeney, M. L., & Crombie, I. K. (1991) · The British Journal of Psychiatry · doi:10.1192/bjp.158.1.24 · Cited by 35
Outcomes of Late-Life Anxiety Disorders During 32 Weeks of Citalopram Treatment
Blank, S., Lenze, E. J., Mulsant, B. H., Dew, M. A., Jordan F., J. F., Shear, M. K., Houck, P. R., Houck, P. R., Houck, P. R., Houck, P. R., et al. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0319 · Cited by 34
Anxiety disorders in the elderly
Carmin, C. N., Wiegartz, P. S., & Scher, C. (2000) · Current Psychiatry Reports · doi:10.1007/s11920-000-0036-0 · Cited by 33 · cited 1×
“Differentiating excessive anxiety from concerns around a recent distressing experience in older people, for example after a fall, can also prove difficult.(14) Anxiety in such scenarios might be expected by both the patient and the clinician and, therefore, the diagnosis of an anxiety disorder might not be considered.”
Clomipramine in the treatment of agoraphobic inpatients resistant to behavioral therapy.
Hoffart, A., Due-Madsen, J., Lande, B., Gude, T., Bille, H., & Torgersen, S. O. (1993) · PubMed · Cited by 29
Electroacupuncture for Refractory Obsessive-Compulsive Disorder: A Pilot Waitlist-Controlled Trial
Zhang, Z., Wang, X., Tan, Q., Jin, G., & Yao, S.-M. (2009) · The Journal of Nervous and Mental Disease · doi:10.1097/nmd.0b013e3181b05fd1 · Cited by 29
Pregabalin Augmentation in Treatment-Resistant Obsessive-Compulsive Disorder
Nicola, M. D., Tedeschi, D., Martinotti, G., Vita, O. D., Monetta, M., Pozzi, G., & Janiri, L. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31822c29a8 · Cited by 28
Novel approaches to treatment of generalized anxiety disorder
Allgulander, C. (2009) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e328333d574 · Cited by 28
Optimizing pharmacotherapy of generalized anxiety disorder to achieve remission.
Pollack, M. H. (2001) · PubMed · Cited by 27
Open-label olanzapine in obsessive-compulsive disorder refractory to antidepressant treatment
Crocq, M. A., Leclercq, P., Guillon, M.-S., & Bailey, P. (2002) · European Psychiatry · doi:10.1016/s0924-9338(02)00673-9 · Cited by 27
van Balkom, A. J. L. M., Emmelkamp, P. M. G., Eikelenboom, M., Hoogendoorn, A. W., Smit, J. H., & van Oppen, P. (2012) · Psychotherapy and Psychosomatics · doi:10.1159/000339369 · Cited by 24
Diagnosis of mental illness in elderly people from ethnic minorities
Lindesay, J. E. B. (1998) · Advances in Psychiatric Treatment · doi:10.1192/apt.4.4.219 · Cited by 23
The views of older people and carers on participation in clinical trials: the PREDICT Study
Bartlam, B., Crome, P., Lally, F., Beswick, A., Cherubini, A., Clarfield, A., Edbrooke, D., Farre, A., Hertogh, C., Lesauskaite, V., et al. (2012) · Clinical Investigation · doi:10.4155/cli.12.4 · Cited by 22 · cited 3×
“Difficulties encountered when undertaking RCTs in older adults include the perceptions of health professionals and practical problems relating to attending for regular assessments.(99) From the patient perspective, older adults have expressed fear of trial treatment and a dislike of the randomisation process.”
A treatment algorithm for the management of anxiety in primary care practice.
Hales, R. E., Hilty, D. A., & Wise, M. G. (1997) · PubMed · Cited by 22
Schutters, S. I. J., van Megen, H. J. G. M., Veen, J. F. V., Schruers, K. R. J., & Westenberg, H. G. M. (2011) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1165 · Cited by 20
Treatment of anxiety with ketazolam in elderly patients.
Bresolin, N., Monza, G., Scarpini, E. A., Scarlato, G., Straneo, G., Martinazzoli, A., Benincà, G., Cattoni, C., De Candia, R., & Belloni, G. (1988) · PubMed · Cited by 19
Treatment Resistant Anxiety Disorders
(2009) · Routledge eBooks · doi:10.4324/9780203893869 · Cited by 19
Effects of quetiapine on cognitive functioning in obsessive???compulsive disorder
de Geus, F., Denys, D. A. J. P., & Westenberg, H. G. M. (2007) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32801182f7 · Cited by 18
Propranolol and Atenolol in the Treatment of Anxiety
Peet, M., & SAADl, A. L. I. (1986) · International Clinical Psychopharmacology · doi:10.1097/00004850-198610000-00005 · Cited by 15
Lack of interventions for anxiety in older people
Voshaar, R. C. O. (2013) · British Journal of Psychiatry · doi:10.1192/bjp.bp.113.127639 · Cited by 13 · cited 2×
“Although there is an increasing awareness of the difficulties in treating anxiety in older adults, there is a lack of an evidence base in this population.(98) Records after duplicates removed (n = 3644) Records identified through database searching (n = 4810) • The Cochrane Library, n = 931 • EMBASE, n = 1116 • MEDLIN…”
Wurthmann, C., Klieser, E., & Lehmann, E. (1995) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/s-2007-996631 · Cited by 9
Psychiatric Assessment and Diagnosis in Older Adults
Meeks, T. W., Lanouette, N. M., Vahia, I. V., Dawes, S., Jeste, D. V., & Lebowitz, B. D. (2009) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.7.1.foc3 · Cited by 7 · cited 1×
“A common symptom of anxiety is deterioration in memory, which could be interpreted as signs of cognitive decline or onset of dementia.(17) Across all age groups anxiety disorders are often associated with pain and physical symptoms that could be a sign of heart disease or another physical illness(7) and, in these case…”
Nakatani, E., & Nakagawa, A. (2008) · Psychotherapy and Psychosomatics · doi:10.1159/000151521 · Cited by 5
Sertraline in Panic Disorder: Initial Treatment Versus Switch Strategy
MAVISSAKALIAN, M. R. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000096248.95165.ac · Cited by 5
Cognitive behavioural therapy for anxiety disorders in later life
Voshaar, R. C. O., Hendriks, G., Keijsers, G. P. J., & van Balkom, A. J. L. M. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007674 · Cited by 5
Khan, A., Atkinson, S. D., Mezhebovsky, I., She, F., Leathers, T., & Pathak, S. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4062 · Cited by 4
Cognitive Behavioral Therapy Versus Psychosurgery for Refractory Obsessive-Compulsive Disorder
Anderson, S. W., & Booker, M. B. (2006) · Journal of Neuropsychiatry · doi:10.1176/jnp.18.1.129 · Cited by 3
Research works printed but not linked: 20
- American Psychiatric Association, 2013, Highlights of Changes from DSM-IV-TR to DSM-5
- Gellis, 2007, Anxiety Disorders among Older Adults (literature review)
- National Collaborating Centre for Mental Health, 2011, Generalised Anxiety Disorder in Adults. The NICE Guideline on Management In Primary, Secondary and Community Care
- National Collaborating Centre for Mental Health, 2005, Post-Traumatic Stress Disorder. The Management of PTSD in Adults and Children in Primary and Secondary Care
- National Collaborating Centre for Mental Health, 2005, Obsessive–Compulsive Disorder: Core Interventions in the Treatment of Obsessive–Compulsive Disorder and Body Dysmorphic Disorder
- National Collaborating Centre for Mental Health, 2013, Social Anxiety Disorder: Recognition, Assessment and Treatment
- National Institute for Health and Care Excellence, 2013, Pathway for Generalised Anxiety Disorder
- National Institute for Health and Care Excellence, 2013, Pathway for Panic Disorder
- National Institute for Health and Care Excellence, 2013, Pathway for Obsessive–Compulsive Disorder and Body Dysmorphic Disorder
- National Institute for Health and Care Excellence, 2013, Pathway for Post-Traumatic Stress Disorder
- National Institute for Health and Care Excellence, 2013, Pathway for Social Anxiety Disorder
- Gale C, Millichamp J. Generalised Anxiety Disorder. Clinical Evidence, 2011. URL: http://clinicalevidence.bmj.com/x/systematic-review/1002/interventions.html (accessed December 2013).
- Kumar S, Malone D. Panic Disorder. Clinical Evidence, 2008. URL: http://clinicalevidence.bmj.com/x/systematic-review/1010/interventions.html (accessed December 2013).
- Bisson JI. Post-Traumatic Stress Disorder. Clinical Evidence, 2009. URL: http://clinicalevidence.bmj.com/x/systematic-review/1005/interventions.html (accessed December 2013).
- Soomro GM. Obsessive Compulsive Disorder. Clinical Evidence, 2011. URL: http://clinicalevidence.bmj.com/x/systematic-review/1004/interventions.html (accessed December 2013).
- Centre for Reviews and Dissemination, 2013, Clinical Effectiveness of Interventions for Treatment-Resistant Anxiety in Older People: a Systematic Review (PROSPERO record)
- Scottish Intercollegiate Guidelines Network, 2013, Search Filters
- Clinical Evidence. Study Design Search Filters. 2013. URL: http://clinicalevidence.bmj.com/x/set/static/ebm/learn/665076.html (accessed December 2013).
- Ginsberg, 2005, Ziprasidone for treatment-resistant generalized anxiety disorder, Prim Psychiatry, 12, 28
- Prasko, 2007, The effect of repetitive transcranial magnetic stimulation (rTMS) add on serotonin reuptake inhibitors in patients with panic disorder: a randomized, double blind sham controlled study, Neuro Endocrinol Lett, 28, 33
Cited by
Stress, glucocorticoids and memory: implications for treating fear-related disorders
de Quervain, D., Schwabe, L., & Roozendaal, B. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2016.155 · Cited by 484
Glucocorticoid-induced enhancement of extinction—from animal models to clinical trials
de Quervain, D. J. ‐., Wolf, O. T., & Roozendaal, B. (2019) · Psychopharmacology · doi:10.1007/s00213-018-5116-0 · Cited by 89
Aligning the many definitions of treatment resistance in anxiety disorders: A systematic review
Bokma, W. A., Wetzer, G. A. A. M., Gehrels, J. B., Penninx, B. W. J. H., Batelaan, N. M., & Balkom, A. L. J. M. (2019) · Depression and Anxiety · doi:10.1002/da.22895 · Cited by 58
“The varying terminology reflects the absence of consensus regarding the criteria for TR (Barton et al., 2014; Cirillo, Freire, & Freire, 2016; Perna & Caldirola, 2017; Stein & Seedat, 2004; Yoshinaga et al., 2016).”
BackgroundInfluentialDomschke, K., Seuling, P. D., Schiele, M. A., Bandelow, B., Batelaan, N. M., Bokma, W. A., Branchi, I., Broich, K., Burkauskas, J., Davies, S. J. C., et al. (2024) · World Psychiatry · doi:10.1002/wps.21177 · Cited by 46
Self-citationClinical characteristics of generalized anxiety disorder: older vs. young adults
Altunöz, U., Kokurcan, A., Kirici, S., Baştuğ, G., & Ozel-Kizil, E. T. (2017) · Nordic Journal of Psychiatry · doi:10.1080/08039488.2017.1390607 · Cited by 38
“However, diagnosis and management of GAD in the older adults remain as a dilemma in clinical practice [9].”
Background
Metadata
- Authors
- Barton, S., Karner, C., Salih, F., Baldwin, D. S., & Edwards, S. J.
- Affiliations
- BMJ Group (United Kingdom) (GB)
- University of Southampton (GB)
- Corresponding author
- Barton, Samantha
- Venue
- Health Technology Assessment
- Published
- 2014-08
- Volume
- 18
- Issue
- 50
- Pages
- 1-60
- ISSN
- 1366-5278 (ISSN-L)
- 2046-4924
- PMC
- PMC4781619
- OpenAlex
- W2081899968
- Cited by
- 36
- References
- 175
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 5 · 2023: 5 · 2022: 3 · 2021: 3 · 2020: 2 · 2019: 4 · 2018: 2 · 2017: 3 · 2016: 4
- FWCI
- 0.32
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Locations
- Health Technology Assessment (publishedVersion, cc-by)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- ePrints Soton (University of Southampton) (acceptedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institute for Health Research (13/39/01)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Keywords
- treatment-resistant anxiety, older adults, anxiety disorders, generalized anxiety disorder, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, phobia, pharmacotherapy, psychological intervention, complementary and alternative medicine, comorbid depression, falls, functional disability, loneliness, absence of evidence, research gaps, treatment non-response
- MeSH terms
- Age Factors, Aged, Anxiety, Humans, Psychotherapy, Anti-Anxiety Agents, Treatment Outcome, Treatment Failure
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.